7. Blinding in Clinical Trials: Who Is Masked, and Why It Matters
After this lesson you can
- Name the bias introduced when participants, clinicians, assessors, analysts or the committee know the arm
- Describe how a matching placebo and a sham procedure are built
- Plan an open-label blinded-endpoint design when the intervention cannot be hidden
- Write an emergency unblinding procedure with a code holder and a log
- Interpret a guess-the-arm result against chance
Video coming soon
Lessons publish daily from November 17, 2026.
This lesson names the five groups that can be blinded and the bias each one's knowledge introduces, and explains why labels like double-blind mean nothing without naming roles. It covers matching placebos and shams, the open-label blinded-endpoint design, unblinding rules and the guess-the-arm check.
Questions and answers
Questions a learner would ask about this lesson. Think through your own answer before you open each one.
- Who can be blinded in a trial, and what does each group's knowledge do?
Show answer
Five groups: participants (expectation, adherence and reporting bias), clinicians (co-intervention and differential withdrawal), outcome assessors (measurement bias), analysts (choice bias) and the data monitoring committee (judgment bias). Blinding keeps knowledge of the assigned intervention from people whose behavior or judgment it would change.
- What does "double-blind" mean?
Show answer
It usually means participant and clinician, but different protocols use it for different pairs. The labels on the ladder from open label to fully blinded mean nothing until someone says which groups are blinded. A protocol should name the roles every time.
- What if the intervention cannot be hidden, as with the Oakhaven program?
Show answer
Use the open-label blinded-endpoint design. Participants and clinicians know the arm, but the outcome assessor, the analyst and the committee do not, with a wall between the program team and the measurement team. The protocol names what stays open, such as expectation and reporting on the symptom score, and how it is watched.
- How should emergency unblinding work?
Show answer
It should be possible, rare and recorded. If the right care does not depend on the arm, the participant is treated and stays blind. If it does, a documented request goes to a code holder outside the program and assessment teams, every break is logged with its reason, and the assessor is not told.
- In the tablet side case, 60 percent of participants guessed their arm correctly. Does that mean blinding failed?
Show answer
No. Chance would give 50 percent, so 60 percent is ten points above chance, which is a signal to investigate, not a verdict. It does not prove blinding failed, invalidate randomization or invalidate the trial, because guesses can follow benefit rather than leaks. The number is reported whatever it is.
Practice quiz
- Question 1Blinding the outcome assessor mainly prevents:
- Question 2A clinician who knows the arm gives extra care to one arm. This bias is called:
- Question 3Allocation concealment and blinding differ in that concealment acts:
- Question 4The Oakhaven program cannot be blinded from participants. Which design keeps the measurement honest?
- Question 5Which Oakhaven endpoint is most exposed when participants know their arm?
- Question 6A matching placebo for a tablet must match:
- Question 7In a blinded tablet trial, 60 percent of participants guess their arm correctly against 50 percent expected by chance. This:
- Question 8Who should hold the unblinding code?
- Question 9In Oakhaven, how is the analyst kept blind?
- Question 10When should participants be asked to guess their arm?
Saved in your browser only: no account, no server.
Design of Clinical Studies is education only. Every lesson follows the fictional Oakhaven Adherence Trial with invented numbers; the course uses no real data and cites no real studies.